Epithelial Ovarian Cancer

Furthermore, while ARMS-PCR panels displayed limited clinicopathological correlations, MethyLight showed significant correlations (P < 0.05). Overall, this pilot study highlights the promise of liquid biopsy-based diagnostics using independent hypermethylated and hypomethylated CpG biomarkers for ovarian cancer detection.

The results of the H-L test showed good fitness. The nomogram model developed in this study exhibits good predictive performance and applicability, and can be used to screen for the risk of recurrence in this population.

In patients demonstrating substantial response to neoadjuvant chemotherapy (CRS 2-3), PARPi maintenance was associated with improved PFS, whereas no benefit was observed for CRS 1. The score may aid counseling regarding PARPi initiation, particularly in BRCA-wildtype patients or where homologous recombination deficiency (HRD) testing access is limited.

These data show that ULK1 differentially regulates mitochondrial degradation across EOC spheroid models through potential mechanisms alternative to canonical autophagy machinery, while reshaping spheroid metabolism and revealing potential therapeutic vulnerabilities in advanced EOC.

Early-phase investigations of TIM-3-targeting strategies further expand the immunotherapeutic landscape, although clinical efficacy remains preliminary. Current evidence underscores that OC is not uniformly responsive to immunotherapy and that rational combination strategies, biomarker-driven patient selection, and improved understanding of tumor immune microenvironment heterogeneity are essential to unlocking the full therapeutic potential of ICI in this disease.

This large clinicogenomic study in an Asian population highlights unique mutational landscapes and survival associations, which may inform personalized treatment strategies.

The CX3CL1-CX3CR1 axis promotes ovarian cancer progression by recruiting MMP-2- and TGF-β-producing macrophages. Targeting CX3CR1-dependent TAM functions may represent a therapeutic strategy for limiting peritoneal dissemination in ovarian cancer.

This study develops and evaluates a CLDN4-directed, IP-containing nanobubble framework for ovarian cancer phototheranostics. The data support ultrasound-associated enhancement of tumor IP-related delivery/retention, photothermal tumor suppression, and treatment-associated immune activation under the tested workflow, while defining areas for further optimization of peptide stability, nanobubble pharmacology, acoustic dosing, and translational safety.

NACT with atezolizumab was feasible and did not delay ICS. Translational parameters showed heterogeneous changes reflecting both immune activation and adaptive immune resistance.

Mechanistically, IGF2BP3 binds to m6A-modified FASN mRNA to enhance its stability, and pharmacological inhibition of FASN by orlistat reverses IGF2BP3-mediated oncogenic effects and WNT/β-catenin activation. In vivo and in vitro experiments confirm that knocking down either IGF2BP3 or FASN reverses these malignant phenotypes. These findings highlight a novel m6A-dependent IGF2BP3-FASN-WNT axis that drives EOC progression, providing a potential biomarker for targeted therapy.

P=N/A, N=0, Withdrawn, University Hospital, Tours | N=320 --> 0 | Not yet recruiting --> Withdrawn

Complete remission was obtained using stereotactic radiotherapy to the brain lesions, followed by platinum-based chemotherapy and maintenance therapy with bevacizumab and olaparib...Their role in this setting remains emerging and primarily supported by limited case reports and small series. Further studies are required to better define their role.